Pyrilutamide (KX-826) is a topical anti-androgen being developed by Kintor Pharmaceutical for androgenetic alopecia and acne vulgaris. It works by blocking the androgen receptor directly at the follicle, aiming to deliver the anti-androgenic effect of systemic drugs without measurable systemic exposure. The compound has generated significant interest because it targets the same receptor finasteride protects upstream, but through local application rather than circulating hormone reduction. A Chinese Phase 3 trial met its primary endpoint in March 2026, and the developer says a filing in China is next. Here is what the clinical data actually shows, how it compares to existing treatments, and why establishing a baseline before any new treatment matters. BaldingAI helps you lock in that baseline with consistent photo tracking so you have objective data if and when new treatments become available.
TL;DR
- Pyrilutamide is a non-steroidal androgen receptor antagonist applied topically to the scalp for androgenetic alopecia.
- The Chinese Phase 3 stage of the registrational trial met its primary endpoint on 18 March 2026: the 1.0% twice-daily arm gained 15.33 hairs per square centimetre from baseline against 4.68 in the vehicle arm, a difference of 10.65 (P < 0.0001).
- Unlike finasteride (a 5-alpha reductase inhibitor), pyrilutamide blocks dihydrotestosterone at the receptor level without reducing systemic DHT.
- It differs from clascoterone in its binding profile and local metabolism rate.
- The positive Phase 3 result is Chinese. Kintor says it will start an NDA submission with the Chinese regulator; there is no announced US filing, and the US trial that has completed was a Phase 2.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
What is pyrilutamide and how does it work?
Pyrilutamide (chemical designation KX-826) is a non-steroidal androgen receptor (AR) antagonist. It binds competitively to the androgen receptor in dermal papilla cells, preventing dihydrotestosterone (DHT) from activating the receptor and triggering the signaling cascade that leads to follicular miniaturization. In simple terms: DHT still gets produced and still reaches the follicle, but pyrilutamide blocks the door so it cannot exert its miniaturizing effect.
This mechanism is distinct from finasteride and dutasteride, which are 5-alpha reductase inhibitors. Those drugs reduce systemic DHT levels by blocking the enzyme that converts testosterone to DHT. The reduction is systemic, which is why finasteride can cause sexual side effects in a subset of users: serum DHT drops by roughly 70%. Pyrilutamide does not alter circulating DHT levels at all. It acts locally at the follicle, and preclinical pharmacokinetic data from Kintor shows rapid local metabolism with minimal systemic absorption.
The concept of topical androgen receptor blockade is not new. Clascoterone (Breezula/Winlevi), developed by Cassiopea, is another topical AR antagonist that received FDA approval for acne in 2020 and has been in trials for androgenetic alopecia. Pyrilutamide and clascoterone share the same general mechanism but differ in chemical structure, binding affinity profiles, and metabolic half-life at the scalp. Kintor has claimed that pyrilutamide has a higher binding affinity for the androgen receptor than clascoterone, though head-to-head comparison data in human hair follicles has not been published.
Phase II clinical trial results
Kintor Pharmaceutical completed a Phase II randomized, double-blind, placebo-controlled trial in China in 2022. The study enrolled 123 male participants with androgenetic alopecia (Norwood-Hamilton grade II through IV) and randomized them to pyrilutamide 0.5% solution or vehicle placebo applied once daily for 24 weeks.
The primary endpoint was change in non-vellus hair count (TAHC) per square centimeter in a target area of the scalp at 24 weeks. The pyrilutamide group showed a mean increase of approximately 22.7 hairs per square centimeter from baseline, compared to a mean increase of approximately 15.1 hairs per square centimeter in the placebo group. The difference was statistically significant (p < 0.05). No serious adverse events were reported, and hormonal panels (including serum testosterone, DHT, FSH, and LH) remained within normal ranges throughout the study, supporting the claim of minimal systemic absorption.
Context matters here. The absolute hair count increase is modest compared to what finasteride trials have demonstrated. In the Phase III finasteride trials (Kaufman et al., 1998, published in the Journal of the American Academy of Dermatology), finasteride 1mg produced a mean increase of approximately 107 hairs in a 5.1 cm2 target area at 24 months, or roughly 21 hairs per square centimeter. Pyrilutamide's 24-week data shows a smaller net effect, but the comparison is imperfect because the trials used different populations, different disease severity baselines, and different measurement timeframes.
How pyrilutamide compares to existing treatments
The key differentiator for pyrilutamide is the side-effect profile, not raw efficacy. Finasteride is effective but carries a risk of sexual side effects (reported in 1.3 to 3.8% of users in clinical trials), which makes some patients reluctant to start it. Dutasteride is more potent but has a similar side-effect concern. Topical finasteride reduces systemic DHT less than oral formulations but does not eliminate it entirely. Pyrilutamide, if the Phase II safety data holds through Phase III, could offer androgen receptor blockade with genuinely negligible systemic hormonal impact.
Compared to clascoterone, the distinction is more nuanced. Both are topical AR antagonists. Clascoterone is a steroidal antiandrogen that is metabolized to cortexolone, while pyrilutamide is non-steroidal with reportedly faster local degradation. The clinical relevance of these pharmacokinetic differences will only become clear when both compounds have robust Phase III data in androgenetic alopecia. As of early 2026, clascoterone's hair loss indication remains in trial, and pyrilutamide's Phase III results have not been fully published.
Minoxidil works through a completely different mechanism (potassium channel opening, vasodilation, prolongation of anagen) and is complementary rather than competing. If pyrilutamide reaches the market, it would most likely be used alongside minoxidil in the same way finasteride currently is: one drug to address the androgenic driver, another to stimulate growth.
Trial status and regulatory timeline
On 18 March 2026 Kintor announced that the Phase 3 stage of its registrational Chinese trial had reached its primary endpoint. The study is described as a multi-centre, randomised, double-blind, vehicle-controlled phase II/III trial with an adaptive design, run across 26 centres in China, testing the 1.0% and 0.5% twice-daily tinctures over 24 weeks of treatment. The 1.0% twice-daily arm gained 15.33 hairs per square centimetre from baseline against 4.68 in the vehicle arm, a difference of 10.65 (P < 0.0001). Kintor said it plans to begin an NDA submission for the 1.0% tincture with the Chinese regulator.
The United States is at an earlier stage than this post previously claimed. The completed US study, NCT05218642, is registered on ClinicalTrials.gov as a Phase 2 trial in 123 male participants, not a Phase 3, and no US Phase 3 for male androgenetic alopecia is registered. A Chinese approval would not make the product available in the United States, and no US filing date has been announced.
Drug development is not linear: unexpected safety signals, manufacturing issues, or inconclusive efficacy data can delay or halt the process. Kintor has faced regulatory delays in China before that extended its own projected timelines.
It is worth tracking this compound, but not worth waiting for it if you are actively losing hair. Androgenetic alopecia is progressive, and every month of follicular miniaturization makes eventual regrowth more difficult. Starting an evidence-based treatment now and adding pyrilutamide later (if approved) is a more rational strategy than delaying treatment entirely.
The gray market and compounding concerns
Pyrilutamide raw powder has been available through chemical suppliers and gray-market vendors since the first trial data was published. Some individuals have been self-compounding topical solutions at home or purchasing pre-made formulations from unregulated sources. This carries real risks: without pharmaceutical-grade quality control, the concentration, purity, stability, and vehicle formulation are unknown. Contaminated or incorrectly concentrated batches can cause scalp irritation, systemic exposure, or simply be inactive.
The trial safety data is from a controlled clinical setting with pharmaceutical-grade drug product. It cannot be extrapolated to homemade preparations. If you are considering pyrilutamide, the responsible approach is to wait for regulatory approval or enroll in a clinical trial through ClinicalTrials.gov.
Why baseline tracking matters before any new treatment
If you are waiting for pyrilutamide, currently on finasteride, or exploring other options, a documented baseline is the single most useful thing you can do right now. Without before-and-after density data captured under consistent conditions, you cannot objectively evaluate whether a treatment is working, stable, or failing.
Capture photos of your hairline, temples, crown, and part line under the same lighting and angle on day one. Repeat every two to four weeks. BaldingAI standardizes this process so each scan is directly comparable, eliminating the noise that comes from different lighting, wet versus dry hair, and camera distance. When you eventually start a new treatment, whether it is pyrilutamide or something else, you will have months of baseline data showing your natural rate of progression. That data transforms vague impressions into clinical-grade evidence you can share with your dermatologist.
Hair loss treatment is a long timeline. A 24-week trial requires 24 weeks of data. A 12-month finasteride assessment requires 12 months. Starting the tracking habit now means you are ready to evaluate any treatment you try, including ones that do not exist yet.
The bottom line
Pyrilutamide is a legitimate clinical candidate for androgenetic alopecia with a sound mechanistic rationale, and its Chinese Phase 3 stage met its endpoint in March 2026. If a Chinese approval follows, it would be the first topical anti-androgen approved specifically for hair loss in men, filling a real gap for patients who want local androgen receptor blockade without systemic hormonal changes.
But it is not available yet, and not in the United States on any announced timeline. The effect sizes are modest, and the gray-market supply is unregulated. If you are losing hair now, evidence-based treatments exist today and should not be deferred in anticipation of a drug that may or may not reach the market on schedule. Track your baseline, start what is proven, and add new tools to your protocol as they become available with proper regulatory backing.
Sources: Kaufman et al. 1998, JAAD, Kintor Pharmaceutical, Phase III KX-826 tincture 1.0% primary endpoint, 18 March 2026, ClinicalTrials.gov NCT05218642 (US Phase 2), Kintor Pharmaceutical pipeline.
